Stability and Predictability of Motor Symptom Control in Patients with Advanced Parkinson's Disease (aPD) Receiving Continuous Subcutaneous Foslevodopa/Foscarbidopa (LDP/CDP)

被引：0
|
作者：
Pahwa, R.
Malaty, I.
Soileau, M.
Fung, V.
Garcia, D. Santos
Carroll, C.
Henriksen, T.
Epstein, A.
Yan, C.
Alobaidi, A.
Shewale, A.
Spiegel, A.
Facheris, M.
Shah, M.
Kukreja, P.
Zamudio, J.
Chaudhuri, K.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
105
引用
收藏
页码：S44 / S45
页数：2
相关论文
共 50 条
  • [21] Foslevodopa/Foscarbidopa in Patients with Advanced Parkinson's Disease: Subgroup Analyses from a Phase 3, Randomized Study
    Soileau, M.
    Fisseha, N.
    Jeong, A.
    Kimber, T.
    Klos, K.
    Robieson, W.
    Talapala, S.
    Vaou, E.
    Zheng, H.
    Facheris, M.
    Hauser, R.
    MOVEMENT DISORDERS, 2023, 38 : S51 - S51
  • [22] An Observational Study of the Efficacy, Safety, and Discontinuation Rate of Foslevodopa/Foscarbidopa in 22 Patients with Advanced Parkinson's disease (PD)
    Kamiyama, D.
    Nishikawa, N.
    Abe, C.
    Iwaki, H.
    Oyama, G.
    Hatano, T.
    Hattori, N.
    MOVEMENT DISORDERS, 2024, 39 : S371 - S371
  • [23] Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
    Soileau, Michael J.
    Aldred, Jason
    Budur, Kumar
    Fisseha, Nahome
    Fung, Victor Sc
    Jeong, Anna
    Kimber, Thomas E.
    Klos, Kevin
    Litvan, Irene
    O'Neill, Daniel
    Robieson, Weining Z.
    Spindler, Meredith A.
    Standaert, David G.
    Talapala, Saritha
    Vaou, Eleni Okeanis
    Zheng, Hui
    Facheris, Maurizio F.
    Hauser, Robert A.
    LANCET NEUROLOGY, 2022, 21 (12): : 1099 - 1109
  • [24] Subcutaneous foslevodopa/foscarbidopa in patients with advanced Parkinson's Disease: results from a randomized, double-blind, double-dummy phase 3 trial
    Soileau, M.
    Spindler, M.
    Aldred, J.
    Budur, K.
    Fisseha, N.
    Fung, V.
    Jeong, A.
    Kimber, T.
    Klos, K.
    Litvan, I.
    O'Neill, D.
    Robieson, W.
    Standaert, D.
    Talapala, S.
    Vaou, E. Okeanis
    Zheng, H.
    Facheris, M.
    Hauser, R.
    MOVEMENT DISORDERS, 2022, 37 : S354 - S354
  • [25] Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report
    Nukariya, Tomonori
    Tezuka, Toshiki
    Okusa, Shohei
    Okochi, Ryotaro
    Sakai, Yuto
    Nihei, Yoshihiro
    Nakahara, Jin
    Seki, Morinobu
    JOURNAL OF MOVEMENT DISORDERS, 2025,
  • [26] Potential Psychosis Induced by a Sustained High Plasma Levodopa Concentration Due to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report
    Tezuka, Toshiki
    Nukariya, Tomonori
    Kizuka, Yuta
    Okusa, Shohei
    Okochi, Ryotaro
    Sakai, Yuto
    Nihei, Yoshihiro
    Nakahara, Jin
    Seki, Morinobu
    JOURNAL OF MOVEMENT DISORDERS, 2024, 17 (04) : 453 - 455
  • [27] Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial (vol 21, pg 1099, 2022)
    Soileau, M. J.
    Aldread, J.
    Budur, K.
    LANCET NEUROLOGY, 2023, 22 (03): : E5 - E5
  • [28] Foslevodopa/Foscarbidopa Subcutaneous Infusion Shows Similar Infusion Site Reaction Severity Score Across Range of Infusion Rates in Patients with Parkinson's Disease
    Schlachter, L.
    Stodtmann, S.
    Talapala, S.
    Facheris, M.
    Rosebraugh, M.
    MOVEMENT DISORDERS, 2023, 38 : S49 - S49
  • [29] Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life with Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson's disease (PD): Interim Results From an Ongoing Open Label Extension
    Bergquist, F.
    Aldred, J.
    Carroll, C.
    Danielsen, E.
    Facheris, M.
    Gupta, R.
    Jeong, A.
    Spiegel, A.
    Fung, V.
    MOVEMENT DISORDERS, 2024, 39 : S322 - S323
  • [30] Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
    Jason Aldred
    Eric Freire-Alvarez
    Alexander V. Amelin
    Angelo Antonini
    Bruno Bergmans
    Filip Bergquist
    Manon Bouchard
    Kumar Budur
    Camille Carroll
    K. Ray Chaudhuri
    Susan R. Criswell
    Erik H. Danielsen
    Florin Gandor
    Jia Jia
    Thomas E. Kimber
    Hideki Mochizuki
    Weining Z. Robieson
    Amy M. Spiegel
    David G. Standaert
    Saritha Talapala
    Maurizio F. Facheris
    Victor S. C. Fung
    Neurology and Therapy, 2023, 12 (6) : 1937 - 1958
12345